Affinage

SSTR5

Somatostatin receptor type 5 · UniProt P35346

Length
364 aa
Mass
39.2 kDa
Annotated
2026-04-28
53 papers in source corpus 18 papers cited in narrative 18 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SSTR5 is a Gi/Go-coupled somatostatin receptor that tonically suppresses hormone secretion and cell proliferation across endocrine, gastrointestinal, and immune cell types. It inhibits adenylyl cyclase to lower cAMP and suppresses L-type Ca²⁺ channel currents via pertussis toxin-sensitive G proteins, while independently inhibiting intracellular calcium mobilization through the phospholipid/Ca²⁺ pathway to exert antiproliferative effects distinct from SSTR2's phosphatase-dependent mechanism (PMID:8102785, PMID:8684611, PMID:7878022). In pancreatic β-cells, SSTR5 is the principal receptor mediating somatostatin-dependent inhibition of insulin secretion, as demonstrated by global and β-cell-specific knockouts that produce hyperinsulinemia and altered glucose homeostasis, and it localizes to primary cilia where it lowers ciliary cAMP and promotes GLI2 nuclear translocation (PMID:12657967, PMID:15919085, PMID:38549435). SSTR5 also suppresses GH and TSH release from pituitary cells, inhibits GLP-1 secretion in intestinal crypts, upregulates colonic MUC2 via Notch-Hes1 pathway suppression, and exerts anti-inflammatory effects by reducing TNF-α production and promoting M2 macrophage polarization (PMID:9045884, PMID:31556942, PMID:31733832, PMID:38331094).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 1993 High

    Cloning and functional expression of SSTR5 established it as a Gi-coupled receptor with a pharmacological profile distinct from other SSTR subtypes, resolving the question of whether a fifth somatostatin receptor subtype existed with unique ligand selectivity.

    Evidence Radioligand binding and cAMP accumulation assays in transfected CHO-K1/COS-1 cells

    PMID:8102785

    Open questions at the time
    • Downstream effectors beyond cAMP not yet identified
    • In vivo physiological role unknown
  2. 1994 High

    Cloning of human SSTR5 revealed species-dependent pharmacology — the clinically used analogue octreotide (SMS 201-995) did not inhibit cAMP at human SSTR5 — establishing that rodent pharmacology could not be directly extrapolated to human drug design.

    Evidence Stable expression in CHO-K1 cells, radioligand binding, cAMP assay, RT-PCR tissue distribution

    PMID:8078491

    Open questions at the time
    • Structural basis for species selectivity difference unknown
    • Native tissue function not yet demonstrated
  3. 1995 High

    SSTR5's antiproliferative mechanism was shown to operate through inhibition of the phospholipid/Ca²⁺ pathway rather than tyrosine phosphatase activation, distinguishing it mechanistically from SSTR2 and identifying a second effector arm.

    Evidence Cell proliferation assay, intracellular calcium measurement, phosphatase activity assay with pharmacological inhibitors in CHO-SSTR5 cells

    PMID:7878022

    Open questions at the time
    • Identity of the phospholipase/Ca²⁺ intermediary not defined
    • Relevance to native tissues expressing SSTR5 not confirmed
  4. 1996 High

    SSTR5 was shown to inhibit L-type Ca²⁺ channels through pertussis toxin-sensitive Gi/Go proteins and to undergo pronounced desensitization, providing the first direct electrophysiological characterization of SSTR5 effector coupling.

    Evidence Whole-cell patch clamp in AtT-20 pituitary cells with pertussis toxin and selective agonist/antagonist pharmacology

    PMID:8684611

    Open questions at the time
    • Specific Gα subunit identity not resolved
    • Desensitization mechanism (GRK/β-arrestin involvement) not defined
  5. 1997 High

    SSTR5-selective pharmacology in primary human pituitary cells demonstrated that SSTR5 is sufficient to suppress GH and TSH secretion but not prolactin, assigning specific endocrine functions to this subtype in humans.

    Evidence Primary human fetal pituitary cultures and acromegalic tumor cells treated with SSTR5-selective analogues, hormone RIA/ELISA

    PMID:9045884

    Open questions at the time
    • Relative contribution of SSTR5 vs. SSTR2 in combined pituitary signaling not quantified
    • Downstream intracellular pathway in pituitary GH suppression not mapped
  6. 2003 High

    Genetic ablation of SSTR5 in mice proved that SSTR5 is the receptor mediating somatostatin's tonic inhibition of insulin secretion in pancreatic islets, resolving which SSTR subtype controls β-cell insulin release.

    Evidence SSTR5 global knockout mice, isolated perfused pancreas, octreotide challenge, somatostatin immunoneutralization

    PMID:12657967

    Open questions at the time
    • Cell-autonomous vs. paracrine contribution not yet separated
    • Compensatory SSTR expression changes not fully characterized
  7. 2004 High

    Double knockout of SSTR1 and SSTR5 produced islet hyperplasia and hyperinsulinemia exceeding single knockouts, establishing that SSTR1 and SSTR5 coordinate to restrain insulin secretion and β-cell mass.

    Evidence SSTR1/SSTR5 double-knockout mice, glucose tolerance tests, perfused pancreas, islet culture

    PMID:15349106

    Open questions at the time
    • Whether SSTR1 and SSTR5 signal through the same or distinct intracellular pathways in islets unclear
  8. 2005 High

    β-cell-specific conditional knockout confirmed cell-autonomous SSTR5 function and revealed age-dependent insulin secretory phenotypes, while global knockouts showed compensatory upregulation of SSTR1 at early ages followed by loss at later ages.

    Evidence Cre-lox β-cell-specific and global SSTR5 knockout mice, glucose/insulin tolerance tests, in vitro islet SST-28 stimulation, immunohistochemistry

    PMID:15919085 PMID:16026801

    Open questions at the time
    • Molecular mechanism of SSTR1 compensatory regulation unknown
    • Whether age-dependent phenotype applies to humans undetermined
  9. 2011 High

    The P335L SNP was identified as a hypofunctional SSTR5 variant that impairs antiproliferative signaling and insulin suppression, linking receptor coding variation to functional output and potential disease susceptibility.

    Evidence Site-directed mutagenesis, transfection in HEK293/MiaPaCa-2/βTC-6 cells, proliferation and insulin secretion assays

    PMID:21249361

    Open questions at the time
    • Structural basis for P335L hypofunction unknown
    • Population frequency and clinical significance not established in patient cohorts
  10. 2019 Medium

    SSTR5 was shown to regulate intestinal physiology through two distinct mechanisms: suppression of the Notch-Hes1 pathway to upregulate colonic MUC2/mucus secretion, and paracrine inhibition of GLP-1 secretion in intestinal crypts by the non-canonical ligand UTS2B.

    Evidence siRNA knockdown and SSTR5 agonist in LS174T cells with Western blot; mouse intestinal crypt/organoid culture with receptor pharmacological antagonism and in vivo peptide administration

    PMID:31556942 PMID:31733832

    Open questions at the time
    • Direct binding of UTS2B to SSTR5 not demonstrated biochemically
    • In vivo relevance of MUC2 regulation in SSTR5 knockout not tested
  11. 2020 Medium

    Cortistatin's suppression of vascular smooth muscle proliferation and autophagy was partially attributed to SSTR5 (shared with SSTR3), extending SSTR5's antiproliferative role to the vasculature.

    Evidence Rat VSMC culture, SSTR3/5 antagonist pharmacology, proliferation and autophagy assays

    PMID:32348837

    Open questions at the time
    • Effect is partial and shared with SSTR3, making specific SSTR5 contribution uncertain
    • No genetic confirmation of SSTR5 involvement
  12. 2023 Medium

    ZDHHC5 was identified as the palmitoyl acyltransferase for SSTR5, and pharmacological inhibition of ZDHHC5 attenuated pancreatic cancer growth dependent on SSTR5 palmitoylation.

    Evidence Single-cell transcriptomics, lomitapide-mediated ZDHHC5 inhibition, cell proliferation assay, in vivo xenograft

    PMID:36774350

    Open questions at the time
    • Direct biochemical identification of palmitoylation sites on SSTR5 not reported
    • Whether palmitoylation affects SSTR5 trafficking, stability, or signaling not distinguished
  13. 2024 Medium

    Multiple 2024 studies expanded SSTR5's functional scope: ciliary localization in β-cells with local cAMP reduction and GLI2 nuclear translocation; anti-inflammatory roles via TNF-α suppression on mast cells and M1-to-M2 macrophage polarization; and human clinical proof that SSTR5 tonically suppresses GH secretion in healthy adults.

    Evidence Live-cell ciliary cAMP biosensor imaging (preprint); TRPV1+ nerve ablation and SSTR5 agonist in murine allergic conjunctivitis; SSTR5 agonist in diabetic corneal wound model; phase I RCT with oral SSTR5 antagonist in humans

    PMID:38331094 PMID:38549435 PMID:38866206 PMID:bio_10.1101_2024.06.05.597562

    Open questions at the time
    • Ciliary cAMP/GLI2 findings from preprint await peer review
    • How ciliary vs. plasma membrane SSTR5 signaling pools are differentially regulated is undefined
    • Anti-inflammatory mechanisms need genetic confirmation in SSTR5 knockout models

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key open questions include: the structural basis for SSTR5's distinct effector coupling and desensitization properties; how SSTR5 palmitoylation by ZDHHC5 modulates trafficking and signaling; the physiological significance of ciliary vs. non-ciliary SSTR5 signaling; and whether SSTR5 coding variants (e.g. P335L) predispose to metabolic or neoplastic disease in human populations.
  • No high-resolution structure of SSTR5 in active or inactive state
  • No systematic human genetic association studies for SSTR5 variants
  • Ciliary signaling findings not yet peer-reviewed or replicated

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 6 GO:0098772 molecular function regulator activity 5
Localization
GO:0005886 plasma membrane 4 GO:0005929 cilium 1
Pathway
R-HSA-162582 Signal Transduction 6 R-HSA-168256 Immune System 2 R-HSA-392499 Metabolism of proteins 1
Partners
GLI2SSTR1SSTR3ZDHHC5

Evidence

Reading pass · 18 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1993 SSTR5 was cloned and pharmacologically characterized: it binds somatostatin analogues with distinct selectivity profiles compared to other SSTR subtypes, and mediates inhibition of forskolin-stimulated cAMP accumulation in CHO/COS cells, consistent with Gi coupling. Radioligand binding competition assay, cAMP accumulation assay in transfected CHO-K1/COS-1 cells Molecular pharmacology High 8102785
1994 Human SSTR5 was cloned and expressed; it mediates inhibition of forskolin-stimulated cAMP accumulation via Gi, but unlike rat SSTR5, the clinically used analogue SMS 201-995 does not inhibit cAMP in human SSTR5-expressing cells, demonstrating species-dependent pharmacology. Human SSTR5 mRNA is selectively expressed in small intestine, heart, adrenal, cerebellum, pituitary, placenta, and skeletal muscle. Stable expression in CHO-K1 cells, radioligand binding, cAMP accumulation assay, RT-PCR for tissue distribution Molecular pharmacology High 8078491
1995 SSTR5 mediates antiproliferative effects of the somatostatin analogue RC-160 through inhibition of intracellular calcium mobilization (inositol phospholipid/Ca2+ pathway), a mechanism distinct from SSTR2 (which acts via tyrosine phosphatase). SSTR5-expressing CHO cells showed RC-160 inhibition of CCK-stimulated Ca2+ and CCK-induced proliferation, and this effect was not blocked by phosphatase inhibitors. Cell proliferation assay, intracellular calcium measurement, phosphatase activity assay, pharmacological inhibitors in CHO cells stably expressing SSTR5 Proceedings of the National Academy of Sciences of the United States of America High 7878022
1996 SSTR5 couples to L-type Ca2+ channels in AtT-20 pituitary cells via pertussis toxin-sensitive G proteins (Gi/Go), mediating inhibition of Ca2+ currents. SSTR5-mediated inhibition undergoes pronounced desensitization upon agonist pretreatment, in contrast to SSTR2. The compound L362,855 acts as an antagonist/partial agonist at SSTR5. Whole-cell patch clamp electrophysiology, pertussis toxin pretreatment, selective agonist/antagonist pharmacology in AtT-20 cells Neuroscience High 8684611
1997 SSTR5 mediates somatostatin-induced suppression of GH and TSH secretion in primary human fetal pituitary cultures; SSTR5-selective analogue exclusively inhibited GH in acromegalic tumor cells, demonstrating SSTR5 is sufficient for GH and TSH regulation but not prolactin suppression (which requires SSTR2). Primary human fetal pituitary cell culture, SSTR subtype-selective analogue treatment, hormone secretion assays (RIA/ELISA), radioligand binding The Journal of clinical investigation High 9045884
2003 Pancreatic somatostatin inhibits insulin secretion through SSTR5 in mouse pancreas: SSTR5-knockout mice showed enhanced glucose-stimulated insulin secretion at 12 months; octreotide suppressed insulin secretion in wild-type but not SSTR5-/- mice; immunoneutralization of somatostatin increased insulin in WT but decreased it in knockouts. Isolated perfused mouse pancreas model, SSTR5 global gene knockout, somatostatin immunoneutralization, octreotide pharmacological challenge Pancreas High 12657967
2004 Double-gene ablation of SSTR1 and SSTR5 results in islet hyperplasia, hyperinsulinemia, and improved glucose tolerance in mice; isolated SSTR1/5-/- islets showed no response to somatostatin peptides, confirming both receptors coordinately regulate insulin secretion and glucose homeostasis. Double-gene knockout mouse model, intraperitoneal glucose tolerance test, isolated perfused pancreas, islet culture, immunohistochemistry Surgery High 15349106
2005 Beta-cell-specific conditional knockdown of SSTR5 (using Cre-lox) causes glucose intolerance with absent insulin response and reduced serum insulin at 3 months, and persistently elevated insulin at 12 months; SSTR5-deficient islets do not respond to SST-28 stimulation, confirming SSTR5's direct role in beta-cell insulin secretion. Conditional Cre-lox knockout in pancreatic beta cells, glucose tolerance test, insulin tolerance test, in vitro islet stimulation with SST-28, immunohistochemistry FEBS letters High 15919085
2005 Global SSTR5 knockout mice show age-dependent glucose regulation changes: glucose intolerance at 3 months (despite normal insulin secretion) and basal hypoglycemia with hyperinsulinemia at 12 months; SSTR1 expression increases compensatorily in islets at 3 months but becomes absent at 12 months, suggesting coordinate regulation between SSTR1 and SSTR5. Global SSTR5-/- mouse model, glucose tolerance test, in vitro pancreas perfusion, immunohistochemistry for SSTR1/SST/insulin The Journal of surgical research High 16026801
2011 The P335L single nucleotide polymorphism of SSTR5 produces a hypofunctional receptor: overexpression of SSTR5-L335 (vs. P335) in pancreatic cancer cells enhanced proliferation, blocked the inhibitory effect of SSTR5-selective agonist RPL-1980 on proliferation and glucose-stimulated insulin secretion, and increased PDX-1 expression. Site-directed mutagenesis, transient transfection in HEK293/Mia PaCa-2/β-TC-6 cells, MTS proliferation assay, insulin ELISA, SNP genotyping World journal of surgery High 21249361
2019 SST/SSTR5 signaling upregulates colonic MUC2 expression and mucus secretion through suppression of the Notch-Hes1 pathway; SSTR5-specific siRNA knockdown abolished SST-induced MUC2 upregulation, and SSTR5 agonist L817,818 replicated the effect. siRNA knockdown of SSTR5 in LS174T cells, SSTR5 agonist treatment, Western blot for NICD and Hes1, MUC2 expression assay, in vivo octreotide administration in mice Biochemical and biophysical research communications Medium 31733832
2019 UTS2B (urotensin 2B), produced by a novel enteroendocrine cell type, inhibits GLP-1 secretion through SSTR5 (not its cognate receptor UTS2R) acting in a paracrine manner in mouse intestinal crypts; SSTR5-mediated inhibition of GLP-1 was confirmed using intestinal organoids. Mouse intestinal crypt and organoid culture, receptor identification by pharmacological antagonism, in vivo peptide administration with plasma GLP-1/insulin measurement Endocrinology Medium 31556942
2023 ZDHHC5 catalyzes palmitoylation of SSTR5; pharmacological blockade of ZDHHC5 with lomitapide inhibits SSTR5 palmitoylation and attenuates pancreatic cancer cell growth in vitro and in vivo. Single-cell transcriptomics comparison, ZDHHC5 inhibition with lomitapide, cell proliferation assay, in vivo xenograft model Cell death discovery Medium 36774350
2024 SSTR5 (and SSTR3) localizes to primary cilia of pancreatic β-cells; activation of ciliary SSTR5 lowers ciliary cAMP concentration via Gαi. δ-cells are positioned near primary cilia of other islet cells and direct somatostatin secretion toward cilia. Sustained somatostatin exposure promotes nuclear entry of the transcription factor GLI2 via a ciliary Ca2+ signaling mechanism, extending SSTR5 function beyond acute hormone suppression. Live-cell fluorescence imaging (ciliary cAMP biosensor), subcellular fractionation/localization, islet morphology by confocal microscopy, GLI2 nuclear translocation assay, cilia length measurement in human T2D donor islets bioRxivpreprint Medium bio_10.1101_2024.06.05.597562
2024 TRPV1+ sensory nerves release somatostatin that binds SSTR5 on mast cells and conjunctival fibroblasts to suppress TNF-α production in mast cells and CCL11 (eotaxin-1) expression in fibroblasts, thereby reducing eosinophil infiltration in allergic conjunctivitis. TRPV1+ nerve ablation (resiniferatoxin), TRPV1 blockade, SST-SSTR5 agonist treatment, in vivo murine allergic conjunctivitis model, gene expression and cell infiltration analysis Mucosal immunology Medium 38331094
2024 Activation of SSTR5 with the agonist L-817,818 reduces inflammatory response after corneal epithelial injury and promotes re-epithelialization and nerve regeneration in diabetic mice, acting by inhibiting neutrophil infiltration and shifting macrophage polarization from M1 to M2. Topical SST/SSTR5 agonist (L-817,818) administration, streptozotocin diabetic mouse corneal wound model, gene expression, immunofluorescence for macrophage polarization, neutrophil quantification Mucosal immunology Medium 38866206
2024 SSTR5 antagonism (with oral SCO-240) stimulates robust growth hormone (GH) secretion in healthy humans without affecting other pituitary hormones, demonstrating that endogenous SSTR5 tonically suppresses GH release in vivo. Phase I randomized double-blind placebo-controlled human clinical trial with pharmacokinetic and pharmacodynamic readouts (serum GH, insulin, GLP-1, gallbladder contractions) Clinical pharmacology and therapeutics High 38549435
2020 Cortistatin suppresses angiotensin II-induced vascular smooth muscle cell proliferation and autophagy partially through SSTR3 and SSTR5; blocking SSTR3 and SSTR5 with antagonists partially abrogated cortistatin's anti-proliferative and anti-autophagic effects. Rat VSMC culture, CCK-8 proliferation assay, Western blot, immunofluorescence, transmission electron microscopy, SSTR3/5 antagonist pharmacology Life sciences Medium 32348837

Source papers

Stage 0 corpus · 53 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1995 Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proceedings of the National Academy of Sciences of the United States of America 279 7878022
1997 Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. The Journal of clinical investigation 266 9045884
1994 Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. The Journal of clinical endocrinology and metabolism 169 7521350
1993 Characterization of cloned somatostatin receptors SSTR4 and SSTR5. Molecular pharmacology 127 8102785
1994 Characterization of cloned human somatostatin receptor SSTR5. Molecular pharmacology 112 8078491
2013 Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Human pathology 85 24182563
1996 Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20. Neuroscience 73 8684611
2015 Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance. International journal of clinical and experimental pathology 72 26722517
2019 Aberrant methylation-mediated downregulation of lncRNA SSTR5-AS1 promotes progression and metastasis of laryngeal squamous cell carcinoma. Epigenetics & chromatin 41 31196171
2003 Pancreatic somatostatin inhibits insulin secretion via SSTR-5 in the isolated perfused mouse pancreas model. Pancreas 38 12657967
2006 Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. Endocrine-related cancer 30 16601280
2005 SSTR5 ablation in islet results in alterations in glucose homeostasis in mice. FEBS letters 30 15919085
1996 The tuberin (TSC2), autosomal dominant polycystic kidney disease (PKD1), and somatostatin type V receptor (SSTR5) genes form a synteny group in the Fugu genome. Genomics 30 8954784
2005 The effect of global SSTR5 gene ablation on the endocrine pancreas and glucose regulation in aging mice. The Journal of surgical research 28 16026801
2004 Double-gene ablation of SSTR1 and SSTR5 results in hyperinsulinemia and improved glucose tolerance in mice. Surgery 28 15349106
2002 Novel polymorphisms in the somatostatin receptor 5 (SSTR5) gene associated with bipolar affective disorder. Molecular psychiatry 27 12192619
2023 Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in preclinical pancreatic cancer models. Cell death discovery 25 36774350
2004 Deficiency of somatostatin (SST) receptor type 5 (SSTR5) is associated with sexually dimorphic changes in the expression of SST and SST receptors in brain and pancreas. Molecular and cellular endocrinology 23 15223137
2019 Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma. Biochemical and biophysical research communications 22 31810606
2018 Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer. Annals of diagnostic pathology 19 30476894
2010 Differential between protein and mRNA expression of CCR7 and SSTR5 receptors in Crohn's disease patients. Mediators of inflammation 17 20150960
2010 SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. Folia histochemica et cytobiologica 17 20529830
1998 Cloning of the mouse SSTR5 gene. The Journal of surgical research 17 9695740
2017 Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus. Bioorganic & medicinal chemistry 15 28642028
2011 The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function. World journal of surgery 15 21249361
1993 Human somatostatin receptor genes: localization of SSTR5 to human chromosome 20p11.2. Genomics 14 8244401
2019 Somatostatin stimulates colonic MUC2 expression through SSTR5-Notch-Hes1 signaling pathway. Biochemical and biophysical research communications 13 31733832
2015 mRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer. World journal of surgical oncology 13 25890201
2011 Somatostatin receptors SSTR2 and SSTR5 are expressed in the human thoracic duct. Lymphology 13 21667819
2020 The role of somatostatin and its receptors (sstr2, sstr5) in the contractility of gilt inflamed uterus. Research in veterinary science 12 33002813
2017 Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma). Medical science monitor : international medical journal of experimental and clinical research 12 28434012
2012 Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation. Pituitary 12 21744088
2020 Cortistatin ameliorates Ang II-induced proliferation of vascular smooth muscle cells by inhibiting autophagy through SSTR3 and SSTR5. Life sciences 11 32348837
2017 Discovery of novel somatostatin receptor subtype 5 (SSTR5) antagonists: Pharmacological studies and design to improve pharmacokinetic profiles and human Ether-a-go-go-related gene (hERG) inhibition. Bioorganic & medicinal chemistry 9 28622905
2013 Somatostatin receptor 1 (SSTR1) and somatostatin receptor 5 (SSTR5)expression in hepatocellular carcinoma. Hepato-gastroenterology 9 24634938
2003 Analysis of transmission of novel polymorphisms in the somatostatin receptor 5 (SSTR5) gene in patients with autism. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 7 12898583
2024 TRPV1+ sensory nerves suppress conjunctival inflammation via SST-SSTR5 signaling in murine allergic conjunctivitis. Mucosal immunology 6 38331094
2010 Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5? Endokrynologia Polska 6 20464704
2024 Activation of the SST-SSTR5 signaling pathway enhances corneal wound healing in diabetic mice. Mucosal immunology 5 38866206
2022 Identification of SSTR5 Gene Polymorphisms and Their Association With Growth Traits in Hulun Buir Sheep. Frontiers in genetics 5 35559027
2019 UTS2B Defines a Novel Enteroendocrine Cell Population and Regulates GLP-1 Secretion Through SSTR5 in Male Mice. Endocrinology 4 31556942
2008 [Somatostatin receptors expression (SSTR1-SSTR5) in pheochromocytomas]. Przeglad lekarski 4 19140390
2011 SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes. Surgery 3 22136833
2023 Discovery and exploration of novel somatostatin receptor subtype 5 (SSTR5) antagonists for the treatment of cholesterol gallstones. European journal of medicinal chemistry 2 38070432
2025 The mechanism of lncRNA SSTR5-AS1 promoting ferroptosis resistance and immune escape in ovarian cancer cells by recruiting STAT3 to regulate SLC7A11 expression. Cancer genetics 1 40716132
2024 Pituitary Adenoma: SSTR2 rs2236750, SSTR5 rs34037914, and AIP rs267606574 Genetic Variants, Serum Levels, and Ki-67 Labeling Index Associations. Medicina (Kaunas, Lithuania) 1 39202532
2024 LncRNA SSTR5-AS1 promotes esophageal carcinoma through regulating ITGB6/JAK1/STAT3 signaling. Epigenomics 1 39234955
2007 [Expression and their clinical significance of SSTR2A, SSTR5 and EGFR in non-small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 1 21110926
2025 Hypermethylated Long Non-Coding RNA Genes KCNK15-AS1, MAGI2-AS3, and SSTR5-AS1 in Ovarian Cancer and Their Diagnostic Potential. Bulletin of experimental biology and medicine 0 41023574
2025 Upregulation of lncRNA SSTR5-AS1 promotes osteoblast differentiation and reduces apoptosis. Journal of orthopaedic surgery and research 0 41444600
2024 Oral SSTR5 Antagonist SCO-240 for Growth Hormone Stimulation: A Phase I Single-Dose Study in Healthy Individuals. Clinical pharmacology and therapeutics 0 38549435
2018 Retracted: Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma). Medical science monitor : international medical journal of experimental and clinical research 0 30142144
2005 [Production and preliminary characteristics of polyclonal antibodies specific to SSTR2A and SSTR5 receptors in the pituitary gland]. Endokrynologia Polska 0 16335667